U.S. markets close in 1 hour 40 minutes

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
44.60-0.15 (-0.34%)
A partir del 02:20PM EDT. Mercado abierto.

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
Netherlands
31 30 253 8800
https://www.merus.nl

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo172

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Sven Ante Lundberg M.D.CEO, President & Executive Director953.06kN/D1963
Mr. Gregory D. PerryChief Financial Officer63.76kN/D1960
Mr. Peter B. Silverman J.D.EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal601.19k947.4k1978
Dr. Hui Liu Ph.D.Chief Business Officer, Executive VP & Head of Merus U.S.597.7kN/D1967
Dr. Andrew Joe M.D.Chief Medical Officer & Senior VP692.74kN/D1967
Dr. Hennie HoogenboomCo-Founder and Scientific AdvisorN/DN/DN/D
Harry ShumanChief Accounting OfficerN/DN/DN/D
Mr. Cornelis Adriaan de Kruif Ph.D.CTO & Executive VP350.85kN/D1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPN/DN/DN/D
Kathleen FarrenIR & Corporate Communications OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Gestión corporativa

La calificación ISS Governance QuickScore de Merus N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.